LGBCL: phase 2 study of intensified rituximab induction and maintenance

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with newly diagnosed or rituximab-naive low-grade B-cell lymphoma (LGBCL), intensified rituximab (Rituxan) induction and maintenance delivered tolerable, impressive efficacy

Why this matters

  • Risk scoring systems such as Sokal and European Treatment and Outcome Study (EUTOS) currently incorporate peripheral blood (PB) parameters.

Study design

  • Phase 2 study to investigate the safety and efficacy of rituximab (Rituxan) as 8 weekly doses of induction and 2 y maintenance therapy in 36 patients with newly diagnosed or rituximab-naive LGBCL.
  • Funding: Grant-in-Aid for Clinical Research from the National Hospital Organization.

Key results

  • 77.8% completed therapy.
  • 83.3% overall response rate.
  • 72.2% complete response rate.
  • 76.7% 3-y PFS.
  • 97.0% 3-y OS.
  • No significant difference in 3-y OS by tumor burden (P=.094).
  • 5 patients experienced grade 3 adverse events.

Limitations

  • Limited sample size.